NEW YORK--(BUSINESS WIRE)--OMRIX Biopharmaceuticals, Inc. (“OMRIX” or the “Company”) (NASDAQ: OMRI), a commercial-stage biopharmaceutical company that develops and markets biosurgical and antibody-based products, announced today that it has commenced a Phase 1 clinical trial for its Fibrin Patch product for the management and rapid control of bleeding including severe bleeding in surgery.
